Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 52-Week High – Should You Buy?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $41.95 and last traded at $39.4550, with a volume of 2611 shares. The stock had previously closed at $39.45.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CNTA shares. Lifesci Capital cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Needham & Company LLC cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their price objective for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $40.70.

Centessa Pharmaceuticals Trading Up 0.4%

The business has a 50 day moving average price of $32.87 and a 200-day moving average price of $27.75. The company has a current ratio of 8.57, a quick ratio of 8.57 and a debt-to-equity ratio of 0.21. The company has a market cap of $5.91 billion, a P/E ratio of -26.92 and a beta of 1.14.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). Analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the sale, the insider owned 57,645 shares in the company, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the sale, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This trade represents a 39.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 348,063 shares of company stock worth $9,404,152. Company insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. bought a new position in Centessa Pharmaceuticals during the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd bought a new position in Centessa Pharmaceuticals during the 4th quarter worth $36,000. T. Rowe Price Investment Management Inc. increased its position in Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after buying an additional 1,516 shares during the period. Wells Fargo & Company MN increased its position in Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after buying an additional 1,008 shares during the period. Finally, Knott David M Jr bought a new position in Centessa Pharmaceuticals during the 4th quarter worth $100,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.